Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of N-acetylcysteine in reducing infection risk in alcoholic hepatitis
2014-004522-17Phase 3Unknown
- Sponsor
- Imperial College London
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of acetylcysteine in alcoholic hepatitis (AH) (2 arms), sponsored by Imperial College London. Primary endpoint: Monocyte oxidative burst improvement after 24 hours of NAC therapy. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2014-004522-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004522-17.